Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma

International Journal of Cancer

Volumn 73, Issue 3, 1997, Pages 309-316

  Enk, Alexander H ^a   Jonuleit, Helmut ^a   Saloga, Joachim ^a   Knop, Jürgen ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12;

ANTIGEN PRESENTATION; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MEDIATOR RELEASE; MELANOMA; PHENOTYPE; PRIORITY JOURNAL; SILENCER GENE; SKIN METASTASIS; SUPERNATANT; T LYMPHOCYTE ACTIVATION;

ANTIGENS, CD; ANTIGENS, CD86; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL DIVISION; CISPLATIN; CYTOKINES; DENDRITIC CELLS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-2; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 0030724702     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3     Document Type: Article

References (29)

1. ALIJAGIC, S., MÖLLER P., ARTUC, M., JURGOVSKY, K., CZARNETZKY, B.M. and SCHADENDORF, D., Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation. Europ. J. Immunol., 25, 3100-3107 (1995).
2. ARTEAGA, C.L., HURD, S.D., WINNIER, A.R., JOHNSON, M.D., FENDLY, B.M. and SWAJETZKI, B., Anti-TGFb antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGFb interactions in human breast cancer progression. J. clin. Invest., 92, 2569 (1993).
3. BECKER, Y., Dendritic cell activity against primary tumors. In Vivo. 7, 187-192 (1993).
4. BOON, T., CEROTTINI, J.-C., VAN DEN EYNDE, B., VAN DER BRUGGEN, P. and VAN PEL, A., Tumor antigens recognized by T lymphocytes. Ann. Rev. Immunol., 12, 337-355 (1994).
5. BRUNDA, M.J., LUISTRO, L., WARRIER, R.R., WRIGHT, R.B., HUBBARD. B.R., ZITA, P. and GATELY, M., Antitumor and antimetastatic activity of IL-12 against murine tumors. J. exp. Med., 178, 1223-1230 (1993).
6. BUELENS, C., WILLEMS, F., DELAVUX, A., PIERARD, G., DELVILLE, J.-P. and SCHMITT, D., Interleukin-10 differentially regulates B7-1 (CD80) and B7-2 (CD86) expression on human peripheral blood dendritic cells. Europ. J. Immunol., 25, 2668-2672 (1995).
7. CELLUZI, C.M., MAYORDOMO, J.I., STORKUS, W.J., LOTZE, M.T. and FALO, L.D., Peptide-pulsed dendritic cells induce antigen-specific. CTL-mediated protective tumor immunity. J. exp. Med., 183, 283-287 (1946).
8. CHEN, L., MCGOWAN, P., ASHE, S., JOHNSTON, J., LI, Y. and SINAWITCH, P., Tumor immunogenicity determines the effect of B7 co-stimulation on T cell mediated tumor immunity. J. exp. Med., 179, 523-532 (1994).
9. DUMMER, W., BASTIAN, B., ERNST, N., SCHÄNZLE, C., SCHWAAF, A. and BRÖCKER, E.B., Interleukin-10 production in malignant melanoma: preferential detection of IL-10 secreting tumor cells in metastatic lesions. Int. J. Cancer 66, (1996).
10. ENK, A.H., ANGELONI, V.L., UDEY, M.C. and KATZ, S.I., Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J. Immunol., 151, 2390-2398 (1993).
11. + T-cell immune responses induced by dendritic cells. Immunology 85, 467-474 (1995).
12. HSU, F.J., BENIKE, C., FRANJONI, F., LILES, T.M., TZERWINSKY, T. and ENGLEMAN, S., Vaccination of patients with B cell lymphoma using autlogous antigen-pulsed dendritic cells. Nature (Med.), 2, 52-55 (1996).
13. KEILHOLZ, U., SCHEIBENBOGEN, C., TILGEN, W., BERGMANN, L., WEIDMANN, E., KAUFMANN, S. and HUNSTEIN, W., Interferon-alpha and IL-2 in the treatment of metastatic melanoma. Cancer, 72, 607-614 (1993).
14. LANIER, L.L., O'FALLON, S., SOMOZA, C., PHILLIPS, J.H. and LINSLEY, P.S., CD80 and CD86 provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol., 154, 97-105 (1995).
15. LEGHA, S., Current therapy for malignant melanoma. Blackwell, London (1989).
16. LIU, Y., JONES, B., ARUFFO, A., SULLIVAN, K.M., LINSLEY, P.S. and JANEWAY, C., Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J. exp. Med., 175, 437 (1992).
17. MAEURER, M.J., STORKUS, W.J., KIRKWOOD, J.M. and LOTZE, M.T., New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines. Melanoma Res., 6, 11-24 (1996).
18. MAYORDOMO, J.I., ZORINA, T., STORKUS, W.J., ZITVOGEL, L., CELLUZI, C. and LOTZE, M.T., Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature (Med.), 1, 1297-1302 (1995).
19. MCLELLAN, A.D., STARLING, G.C., WILLIAMS, L.A., HOCK, B.D. and HART, D.N., Activation of human peripheral blood dendritic cells induces the CD86 costimulatory molecule. Europ. J. Immunol., 25, 2064-2068 (1995).
20. MITRA, R.S., JUDGE, T.A., NESTLE, F.O., TURKA, L.A. and NICKOLOFF, B.J., Psoriatic skin-derived dendritic cell function is inhibited by exogenous IL-10. Differential modulation of B-1 (CD80) and B7-2 (CD86) expression. J. Immunol., 154, 2668-2677 (1995).
21. OLIVER, R.T.D. and NOURI, A.M.E., T cell immune response to cancer in humans and its relevance for immunodiagnosis and therapy. Cancer Surv., 13, 173 (1991).
22. PAGLIA, P., CHIODONI, C., RODOLFO, M. and COLOMBO, M.P., Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. exp. Med., 183, 317-322 (1996).
23. ROMANI, N., GRUNER, S., BRANG, D., KÄMPGEN, E., LENZ, A., STEINMAN, R.M. and SCHULER, G., Proliferating dendritic cell progenitors in human blood. J. exp. Med., 180, 83-93 (1994).
24. SCHWARTZ, R., Acquisition of immunologic self-tolerance. Cell, 57, 1073-1075 (1989).
25. STEINMAN, R.M., Dendritic cells and their role in immunogenicity. Ann. Rev. Immunol., 9, 271 (1991).
26. VAN PEL, A., VAN DER BRUGGEN, P., COULIE, P.G., BRICHARD, V.G., LETHÉ, B. and BOON, T., Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol. Rev., 145, 229-250 (1995).
27. YOUNG, J.W. and INABA, K., Dendritic cells as adjuvants for class I MHC-restricted antitumor immunity. J. exp. Med., 183, 7-11 (1996).
28. ZHOU, L.-J. and TEDDER, T.F., Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superlamily. J. Immunol., 154, 3821-3835 (1995).
29. ZITVOGEL, L., MAYORDOMO, J.I., TJANDRAWAN, T., DELEO, A.B., CLARKE, M.R., FINN, O. and STORKUS, W., Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells. B7 costimulation, and Th1-associated cytokines. J. exp. Med., 183, 87-97 (1996).